1、评价健康受试者单次静脉滴注注射用HCP002的耐受性及安全性；2、比较等摩尔剂量的注射用HCP002与注射用伏立康唑在健康人体的耐受性及安全性；3、评价单次静脉滴注给药后HCP002的药代动力学特征；4、评价注射用HCP002单次静脉滴注给药后转化为伏立康唑的药代动力学特征；5、比较等摩尔剂量的注射用HCP002与注射用伏立康唑的药代动力学特征

[Translation]

1. Evaluate the tolerability and safety of a single intravenous drip of HCP002 for injection in healthy subjects; 2. Compare the tolerability and safety of equimolar doses of HCP002 for injection and voriconazole for injection in healthy subjects; 3. Evaluate the pharmacokinetic characteristics of HCP002 after a single intravenous drip; 4. Evaluate the pharmacokinetic characteristics of HCP002 for injection converted to voriconazole after a single intravenous drip; 5. Compare the pharmacokinetic characteristics of equimolar doses of HCP002 for injection and voriconazole for injection

Start Date-

Sponsor / Collaborator

Shaanxi Synthetic Pharmaceutical Co., Ltd.

100 Clinical Results associated with HCP-002

100 Translational Medicine associated with HCP-002

100 Patents (Medical) associated with HCP-002

Literatures (Medical) associated with HCP-002

01 Mar 2022·BioanalysisQ4 · MEDICINE

LC-MS/MS Methods to quantify HCP002 in Human Plasma and Urine: Applications in a Pharmacokinetic Study

Q4 · MEDICINE

Article

Author: Wang, Yong-Qing ; Zhang, Ye ; Sun, Lu-Ning ; Fang, Qiu-Chen ; Chen, Chao ; Li, Xue ; Zhang, Hong-Wen ; Shen, Ye

Aim: HCP002, a phosphate-modified derivative of voriconazole, can improve solubility without using the nephrotoxic solubilizer, sulfobutylether-β-cyclodextrin. To study pharmacokinetics in humans, LC-MS/MS methods to quantify HCP002 in human plasma and urine were developed and validated. Method: After protein precipitation by acetonitrile containing voriconazole-d₃, HCP002 was separated on a ZORBAX SB-Aq column, and LCMS/MS analysis was performed in multi-response monitoring mode. Results: The analytical run time was 3 min. Linearity was observed over the ranges of 0.100-40.0 and 0.400-200 μg/ml in plasma and urine, respectively. Precision and accuracy were within acceptable limits. Sample stability was confirmed. Conclusion: Rapid and reproducible methods quantified HCP002 in urine, and plasma samples were established.

01 Mar 2014·Carbohydrate PolymersQ1 · CHEMISTRY

Structural characterization and immunomodulatory effect of a polysaccharide HCP-2 from Houttuynia cordata

Q1 · CHEMISTRY

Article

Author: Wang, Yi-Fen ; Fung, Kwok-Pui ; Zhou, Xuelin ; Leung, Ping-Chung ; Chan, Judy Yuet-Wa ; Wan, David Chi-Cheong ; Lau, Clara Bik-San ; Chan, Ben Chung-Lap ; Lin, Huang-Quan ; Cheng, Bao-Hui ; Han, Xiao-Qiang

Immunomodulation of natural polysaccharides has been the hot topic of research in recent years. In order to explore the immunomodulatory effect of Houttuynia cordata Thunb., the water extract was studied and a polysaccharide HCP-2 with molecular weight of 60,000 Da was isolated by chromatography using DEAE Sepharose CL-6B and Sephacryl S-500 [corrected] HR columns. The structure characterization of HCP-2 was performed by Fourier transform infrared spectroscopy (FTIR), acidic hydrolysis, PMP derivation, HPLC analysis and nuclear magnetic resonance spectra (NMR). HCP-2 was elucidated as a pectic polysaccharide with a linear chain of 1,4-linked α-D-galacturonic acid residues in which part of the 6-carboxyl groups were methyl esterified and part of 2-hydroxyl groups were acetylated. The bioactivity assays showed that HCP-2 could increase the secretions of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), macrophage inhibitory protein-1α (MIP-1α), macrophage inhibitory protein-1β (MIP-1β), and RANTES (regulated on activation, normal T cell expressed and secreted) in human peripheral blood mononuclear cells (PBMCs), which play critical roles in the innate immune system and shape the adaptive immunity. Our results implied that HCP-2 could be an immune enhancer.

100 Deals associated with HCP-002

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Candidemia	Phase 1	China	Shaanxi Synthetic Pharmaceutical Co., Ltd.	02 Jan 2018
Invasive aspergillosis	Phase 1	China	Shaanxi Synthetic Pharmaceutical Co., Ltd.	02 Jan 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HCP-002

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation